Search Results - "Hee, S W"

Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors by Lim, W.T., Tan, E.H., Toh, C.K., Hee, S.W., Leong, S.S., Ang, P.C.S., Wong, N.S., Chowbay, B.

“…The aim of this study was to determine the maximum tolerated dose (MTD) and the pharmacokinetic profile of Genexol-PM in Asian cancer patients. Patients (N=24)…”
Get full text

High SUV uptake on FDG–PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG–PET/CT staging in lymphoma by Ngeow, J.Y.Y., Quek, R.H.H., Ng, D.C.E., Hee, S.W., Tao, M., Lim, L.C., Tan, Y.H., Lim, S.T.

“…Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in lymphoma staging is still being accumulated and current…”
Get full text

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation by Toh, H C, Chia, W K, Sun, L, Thng, C H, Soe, Y, Phoon, Y P, Yap, S P, Lim, W T, Tai, W M, Hee, S W, Tan, S H, Leong, S S, Tan, E H

“…While nonmyeloablative peripheral blood stem cell transplantation (NST) has shown efficacy against several solid tumors, it is untested in nasopharyngeal…”
Get full text

Development of a repository of individual participant data from randomized controlled trials of therapists delivered interventions for low back pain by Hee, S.W., Dritsaki, M., Willis, A., Underwood, M., Patel, S.

“…Background Individual patient data (IPD) meta‐analysis of existing randomized controlled trials (RCTs) is a promising approach to achieving sufficient…”
Get full text

Recent advances in methodology for clinical trials in small populations: the InSPiRe project by Friede, T, Posch, M, Zohar, S, Alberti, C, Benda, N, Comets, E, Day, S, Dmitrenko, A, Graf, A, Günhan, B. K, Hee, S. W, Lentz, F, Madan, J, Miller, F, Ondra, T, Pearce, M, Röver, C, Tournazi, A, Unkel, S, Ursino, M, Wassmer, G, Stallard, N

“…Orphanet Journal of Rare Diseases, 13:136, 2018 Where there are a limited number of patients, such as in a rare disease, clinical trials in these small…”
Get full text

Radical radiotherapy with high-dose-rate brachytherapy for uterine cervix cancer long-term results by Khor, TH, Tuan, JKL, Hee, SW, Tham, IWK

“…Summary The aim of this is to report the results of radical radiotherapy in carcinoma of the cervix treated by high‐dose rate (HDR) intracavitary brachytherapy…”
Get full text

Safety, effectiveness, and cost effectiveness of decision aids still unclear by Patel, Shilpa, Hee, Siew Wan, Sandhu, Harbinder, Yang, Yaling, Underwood, Martin

Get full text

Improving prediction of mortality, stroke and major bleeding in patients with atrial fibrillation: external validation of the GARFIELD-AF tool in UK primary care electronic records by Apenteng, PN, Prieto-Merino, D, Hee, SW, Lobban, T, Caleyachetty, R, Fitzmaurice, D

“…Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Institute for Health…”
Get full text

Survey amongst health care professionals—Willingness to pay for novel therapies by Chia, W. K., Hee, S. W., Toh, H. C.

“…Abstract only 6138 Background: Singapore’s state sponsored healthcare system provides subsidies for “standard” oncology drugs (patients co-pay). Patients pay…”
Get full text

FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma by Teo, M., Huynh, H. T., Hee, S. W., Phoon, Y. P., Quek, R., Wang, P., Toh, H. C.

“…Abstract only 4538 Background: Hepatocellular carcinoma (HCC) is an aggressive cancer endemic in Asia with few effective treatments. We hypothesize that FOXO3a…”
Get full text

Nonmyeloablative allogeneic blood stem cell transplantation (NMBSCT) ± donor lymphocyte infusion (DLI) for chemorefractory advanced nasopharyngeal carcinoma (NPC) by Toh, H. C., Tan, E. H., Thng, C. H., Yap, S. P., Lee, K. M., Phoon, Y. P., Chua, S., Soe, Y., Hee, S. W., Sun, L.

“…Abstract only 2549 Background: There is emerging clinical evidence for T cell immunotherapy in NPC. We report a NMBSCT regimen that induced mixed chimerism for…”
Get full text